Legend Biotech Corporation (LEGN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 75 | 69 | 117 | 285 | 627 | 1,029 | 1,271 | 1,439 |
| Operating profit | $m | -136 | -56 | ||||||
| Net profit | $m | -266 | -404 | -446 | -518 | -177 | -297 | -92 | -6 |
| EPS reported | $ | -1.60 | -0.50 | ||||||
| Operating cashflow per share | $ | -0.55 | -0.98 | ||||||
| Capex per share | $ | 0.37 | 0.39 | ||||||
| FCF per share | $ | -0.91 | -1.26 | ||||||
| Free cash flow | $m | -168 | -256 | ||||||
| Net debt | $m | -629 | -808 | ||||||
| Book value equity | $m | 1,002 | 1,230 | ||||||
| Book value per share | $ | 5.44 | 6.34 | ||||||
| Number of shares | m | 184.32 | 193.8 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.00 | 3.26 | ||||||
| P/S LTM | x | 3.89 | 3.15 | ||||||
| P/FCF LTM | x | -23.85 | -15.68 | ||||||
| EV/EBITDA LTM | x | -15.15 | -485.77 | ||||||
| EV/Sales LTM | x | 3.42 | 2.65 | ||||||
| Earnings Yield LTM | % | -7.41% | -2.40% | ||||||
| FCF Yield | % | -4.19% | -6.38% | ||||||
| Quality | |||||||||
| ROE | % | -29.62% | -8.70% | ||||||
| ROIC | % | -9.59% | -3.71% | ||||||
| Operating margin | % | -13.27% | -4.42% | ||||||
| Gross margin | % | +60.34% | +56.58% | ||||||
| FCF/Sales | % | -16.33% | -18.48% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +64.04% | +102.68% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.41 | -0.92 | ||||||
| Net Debt/EBITDA | x | 2.10 | 54.49 | ||||||
| EBIT/Net interest | x | -6.38 | -3.38 | ||||||
| Net debt/market cap | % | +7.96% | +4.15% | ||||||
| Net debt/Equity | x | -0.63 | -0.66 | ||||||
| Gross debt/equity | x | 0.41 | 0.23 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Legend Biotech Corporation (LEGN)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free